

Denise Hilfiker-Kleiner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/509970/publications.pdf>

Version: 2024-02-01

171
papers

15,462
citations

19657

61
h-index

18647

119
g-index

181
all docs

181
docs citations

181
times ranked

13547
citing authors

#	ARTICLE	IF	CITATIONS
1	Pathophysiology and risk factors of peripartum cardiomyopathy. <i>Nature Reviews Cardiology</i> , 2022, 19, 555-565.	13.7	21
2	Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart. <i>Cardiovascular Research</i> , 2022, 118, 3016-3051.	3.8	30
3	Chemotherapy-Free Targeted Anti-BCR-ABL+ Acute Lymphoblastic Leukemia Therapy May Benefit the Heart. <i>Cancers</i> , 2022, 14, 983.	3.7	0
4	Loss of vascular endothelial notch signaling promotes spontaneous formation of tertiary lymphoid structures. <i>Nature Communications</i> , 2022, 13, 2022.	12.8	16
5	High prevalence of reduced fertility and use of assisted reproductive technology in a German cohort of patients with peripartum cardiomyopathy. <i>Clinical Research in Cardiology</i> , 2022, , 1.	3.3	1
6	Animal Models of Cardiovascular Complications of Pregnancy. <i>Circulation Research</i> , 2022, 130, 1763-1779.	4.5	10
7	Dissecting the target leukocyte subpopulations of clinically relevant inflammation radiopharmaceuticals. <i>Journal of Nuclear Cardiology</i> , 2021, 28, 1636-1645.	2.1	32
8	What needs to be known about longer-term management and prognosis?. , 2021, , 45-65.		0
9	Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. <i>European Journal of Heart Failure</i> , 2021, 23, 527-540.	7.1	37
10	Genetic and Phenotypic Landscape of Peripartum Cardiomyopathy. <i>Circulation</i> , 2021, 143, 1852-1862.	1.6	65
11	Perhexiline treatment improves toxic effects of Î²â€¢adrenergic receptor stimulation in experimental peripartum cardiomyopathy. <i>ESC Heart Failure</i> , 2021, 8, 3375-3381.	3.1	5
12	Telemonitoring-Supported Exercise Training in Employees With Metabolic Syndrome Improves Liver Inflammation and Fibrosis. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00371.	2.5	6
13	ERBB4 and Multiple MicroRNAs That Target ERBB4 Participate in Pregnancy-Related Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2021, 14, e006898.	3.9	12
14	Peripartum cardiomyopathy: from genetics to management. <i>European Heart Journal</i> , 2021, 42, 3094-3102.	2.2	39
15	Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease. <i>PLoS ONE</i> , 2021, 16, e0255335.	2.5	48
16	Etiology and pathophysiology. , 2021, , 1-11.		1
17	Anthracycline-free tumor elimination in mice leads to functional and molecular cardiac recovery from cancer-induced alterations in contrast to long-lasting doxorubicin treatment effects. <i>Basic Research in Cardiology</i> , 2021, 116, 61.	5.9	11
18	Cardiogenic shock complicating peripartum cardiomyopathy: Importance of early left ventricular unloading and bromocriptine therapy. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 173-182.	1.0	43

#	ARTICLE	IF	CITATIONS
19	Peripartum cardiomyopathy: basic mechanisms and hope for new therapies. <i>Cardiovascular Research</i> , 2020, 116, 520-531.	3.8	33
20	Modulation of cardiac AKT and STAT3 signalling in preclinical cancer models and their impact on the heart. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2020, 1867, 118519.	4.1	17
21	In peripartum cardiomyopathy plasminogen activator inhibitor-1 is a potential new biomarker with controversial roles. <i>Cardiovascular Research</i> , 2020, 116, 1875-1886.	3.8	20
22	Neuraminidase-1 promotes heart failure after ischemia/reperfusion injury by affecting cardiomyocytes and invading monocytes/macrophages. <i>Basic Research in Cardiology</i> , 2020, 115, 62.	5.9	41
23	Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. <i>European Heart Journal</i> , 2020, 41, 3787-3797.	2.2	101
24	Assessment of major mental disorders in a German peripartum cardiomyopathy cohort. <i>ESC Heart Failure</i> , 2020, 7, 4394-4398.	3.1	20
25	Human iPSC-Derived Cardiomyocytes of Peripartum Patients With Cardiomyopathy Reveal Aberrant Regulation of Lipid Metabolism. <i>Circulation</i> , 2020, 142, 2288-2291.	1.6	8
26	Effects of six month personalized endurance training on work ability in middle-aged sedentary women: a secondary analysis of a randomized controlled trial. <i>Journal of Occupational Medicine and Toxicology</i> , 2020, 15, 8.	2.2	5
27	Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology. <i>Clinical Research in Cardiology</i> , 2020, 109, 1197-1222.	3.3	71
28	Employers With Metabolic Syndrome and Increased Depression/Anxiety Severity Profit Most From Structured Exercise Intervention for Work Ability and Quality of Life.. <i>Frontiers in Psychiatry</i> , 2020, 11, 562.	2.6	11
29	Common genetic predisposition for heart failure and cancer. <i>Herz</i> , 2020, 45, 632-636.	1.1	16
30	Outcome in German and South African peripartum cardiomyopathy cohorts associates with medical therapy and fibrosis markers. <i>ESC Heart Failure</i> , 2020, 7, 512-522.	3.1	18
31	miRâˆ’21 and NT-proBNP Correlate with Echocardiographic Parameters of Atrial Dysfunction and Predict Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2020, 9, 1118.	2.4	18
32	Increased prostaglandin-D2 in male STAT3-deficient hearts shifts cardiac progenitor cells from endothelial to white adipocyte differentiation. <i>PLoS Biology</i> , 2020, 18, e3000739.	5.6	3
33	Natriuretic Peptide Receptor 1, a Novel Player in Peripartum Heart Failure. <i>Circulation</i> , 2020, 141, 589-591.	1.6	0
34	Title is missing!. , 2020, 18, e3000739.		0
35	Title is missing!. , 2020, 18, e3000739.		0
36	Title is missing!. , 2020, 18, e3000739.		0

#	ARTICLE	IF	CITATIONS
37	Title is missing!. , 2020, 18, e3000739.		0
38	Title is missing!. , 2020, 18, e3000739.		0
39	Title is missing!. , 2020, 18, e3000739.		0
40	Bromocriptine treatment in patients with peripartum cardiomyopathy and right ventricular dysfunction. <i>Clinical Research in Cardiology</i> , 2019, 108, 290-297.	3.3	29
41	Data on left ventricular expression of STAT3 and AKT in transgenic mouse models with B16F10 melanoma. <i>Data in Brief</i> , 2019, 26, 104508.	1.0	1
42	Fluoxetine induces glucose uptake and modifies glucose transporter palmitoylation in human peripheral blood mononuclear cells. <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 883-891.	3.4	15
43	Long-term follow-up in peripartum cardiomyopathy patients with contemporary treatment: low mortality, high cardiac recovery, but significant cardiovascular co-morbidities. <i>European Journal of Heart Failure</i> , 2019, 21, 1534-1542.	7.1	51
44	Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , 2019, 21, 827-843.	7.1	223
45	Telemonitoring-supported exercise training, metabolic syndrome severity, and work ability in company employees: a randomised controlled trial. <i>Lancet Public Health</i> , The, 2019, 4, e343-e352.	10.0	34
46	Letter by Hilfiker-Kleiner et al Regarding Article, "Modeling Peripartum Cardiomyopathy With Human Induced Pluripotent Stem Cells Reveals Distinctive Abnormal Function of Cardiomyocytes". <i>Circulation</i> , 2019, 139, e990-e991.	1.6	0
47	Effects of personalized endurance training on cellular age and vascular function in middle-aged sedentary women. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1903-1906.	1.8	14
48	Comorbidities and Co-Existing Conditions in Heart Failure Around Pregnancy. <i>Cardiovascular Medicine</i> , 2019, , 63-70.	0.0	0
49	Future cardiovascular risk prediction in women with pregnancy complications: the HUNT is on. <i>European Heart Journal</i> , 2019, 40, 1121-1123.	2.2	3
50	Late onset heart failure after childhood chemotherapy. <i>European Heart Journal</i> , 2019, 40, 798-800.	2.2	18
51	Breastfeeding in Patients With Heart Failure. <i>JACC Basic To Translational Science</i> , 2019, 4, 866-867.	4.1	1
52	Increased Cancer Prevalence in Peripartum Cardiomyopathy. <i>JACC: CardioOncology</i> , 2019, 1, 196-205.	4.0	30
53	Stable depletion of RUNX1-ETO in Kasumi-1 cells induces expression and enhanced proteolytic activity of Cathepsin G and Neutrophil Elastase. <i>PLoS ONE</i> , 2019, 14, e0225977.	2.5	4
54	Sex differences in heart failure. <i>European Heart Journal</i> , 2019, 40, 3859-3868c.	2.2	406

#	ARTICLE	IF	CITATIONS
55	Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia. <i>Leukemia</i> , 2019, 33, 1313-1323.	7.2	20
56	Macrophage Mineralocorticoid Receptor Is a Pleiotropic Modulator of Myocardial Infarct Healing. <i>Hypertension</i> , 2019, 73, 102-111.	2.7	38
57	Cardiology and cardiovascular research in Germany: 5Âyears of gender demographics. <i>Clinical Research in Cardiology</i> , 2019, 108, 218-220.	3.3	3
58	Electrophysiological abnormalities in induced pluripotent stem cellâ€derived cardiomyocytes generated from Duchenne muscular dystrophy patients. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 2125-2135.	3.6	39
59	Treatments targeting inotropy. <i>European Heart Journal</i> , 2019, 40, 3626-3644.	2.2	123
60	Editorial commentary: Peripartum cardiomyopathy: Long-term implications of treatment and management. <i>Trends in Cardiovascular Medicine</i> , 2019, 29, 174-175.	4.9	0
61	Longâ€term prognosis, subsequent pregnancy, contraception and overall management of peripartum cardiomyopathy: practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. <i>European Journal of Heart Failure</i> , 2018, 20, 951-962.	7.1	101
62	A positive feedback loop between IL-1Î², LPS and NEU1 may promote atherosclerosis by enhancing a pro-inflammatory state in monocytes and macrophages. <i>Vascular Pharmacology</i> , 2018, 103-105, 16-28.	2.1	59
63	The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC. <i>European Journal of Heart Failure</i> , 2018, 20, 445-459.	7.1	118
64	Regulation and function of endothelial glycocalyx layer in vascular diseases. <i>Vascular Pharmacology</i> , 2018, 100, 26-33.	2.1	128
65	Pregnancy and Heart Disease: Pregnancy-Associated Hypertension and Peripartum Cardiomyopathy. <i>Current Problems in Cardiology</i> , 2018, 43, 364-388.	2.4	15
66	An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 216-227.	7.1	81
67	Cardiomyopathies and Congenital Heart Disease in Pregnancy. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 1256-1261.	1.8	2
68	miR-125b regulates chemotaxis and survival of bone marrow derived granulocytes in vitro and in vivo. <i>PLoS ONE</i> , 2018, 13, e0204942.	2.5	4
69	Bromocriptine for the Treatment of Peripartum Cardiomyopathy. <i>Cardiac Failure Review</i> , 2018, 4, 1.	3.0	18
70	Complex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology. <i>Cardiovascular Research</i> , 2018, 114, 1287-1303.	3.8	91
71	Reply to â€Bromocriptine for the treatment of peripartum cardiomyopathy: comparison of outcome with a nationwide Danish cohortâ€™. <i>European Heart Journal</i> , 2018, 39, 3478-3478.	2.2	2
72	Optimized Induction of Mitochondrial Apoptosis By Combination Therapies with Venetoclax for Chemotherapy-Free Treatment of BCR-ABL+ Acute Lymphoblastic Leukemia in Preclinical Models. <i>Blood</i> , 2018, 132, 4025-4025.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Low STAT3 expression sensitizes to toxic effects of β^2 -adrenergic receptor stimulation in peripartum cardiomyopathy. <i>European Heart Journal</i> , 2017, 38, ehw086.	2.2	87
74	Olanzapine and aripiprazole differentially affect glucose uptake and energy metabolism in human mononuclear blood cells. <i>Journal of Psychiatric Research</i> , 2017, 88, 18-27.	3.1	12
75	Serelaxin treatment promotes adaptive hypertrophy but does not prevent heart failure in experimental peripartum cardiomyopathy. <i>Cardiovascular Research</i> , 2017, 113, cwv245.	3.8	23
76	Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (<scp>PPCM</scp>). <i>European Journal of Heart Failure</i> , 2017, 19, 1131-1141.	7.1	163
77	Outcome of subsequent pregnancies in patients with a history of peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , 2017, 19, 1723-1728.	7.1	88
78	Risk for life-threatening arrhythmia in newly diagnosed peripartum cardiomyopathy with low ejection fraction: a German multi-centre analysis. <i>Clinical Research in Cardiology</i> , 2017, 106, 582-589.	3.3	67
79	Myofilament Remodeling and Function Is More Impaired in Peripartum Cardiomyopathy Compared with Dilated Cardiomyopathy and Ischemic Heart Disease. <i>American Journal of Pathology</i> , 2017, 187, 2645-2658.	3.8	35
80	Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. <i>European Heart Journal</i> , 2017, 38, 2671-2679.	2.2	243
81	Complete recovery of fulminant peripartum cardiomyopathy on mechanical circulatory support combined with high-dose bromocriptine therapy. <i>ESC Heart Failure</i> , 2017, 4, 641-644.	3.1	13
82	cUMP hydrolysis by PDE3A. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2017, 390, 269-280.	3.0	7
83	Dnmt3a-mediated inhibition of Wnt in cardiac progenitor cells improves differentiation and remote remodeling after infarction. <i>JCI Insight</i> , 2017, 2, .	5.0	12
84	Insulin supplementation attenuates cancer-induced cardiomyopathy and slows tumor disease progression. <i>JCI Insight</i> , 2017, 2, .	5.0	37
85	Cardiomyopathies in Women. , 2017, , 127-139.		0
86	Cardiomyocytes display low mitochondrial priming and are highly resistant toward cytotoxic T α cell killing. <i>European Journal of Immunology</i> , 2016, 46, 1415-1426.	2.9	6
87	Mental disorders in adults with congenital heart disease: Unmet needs and impact on quality of life. <i>Journal of Affective Disorders</i> , 2016, 204, 180-186.	4.1	93
88	Early ivabradine treatment in patients with acute peripartum cardiomyopathy: Subanalysis of the German PPCM registry. <i>International Journal of Cardiology</i> , 2016, 216, 165-167.	1.7	34
89	MicroRNA-Based Therapy of GATA2-Deficient Vascular Disease. <i>Circulation</i> , 2016, 134, 1973-1990.	1.6	46
90	Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , 2016, 18, 1096-1105.	7.1	160

#	ARTICLE	IF	CITATIONS
91	Comparison of the American PPCM Registry Data With International Registries. <i>Journal of the American College of Cardiology</i> , 2016, 67, 733-734.	2.8	0
92	Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. <i>New England Journal of Medicine</i> , 2016, 374, 233-241.	27.0	432
93	In vitro maturation of large-scale cardiac patches based on a perfusable starter matrix by cyclic mechanical stimulation. <i>Acta Biomaterialia</i> , 2016, 30, 177-187.	8.3	50
94	Stable Silencing of RUNX1/ETO Induces Expression of a Shortened PU.1 Variant in t(8;21) Kasumi Cells. <i>Blood</i> , 2016, 128, 2716-2716.	1.4	0
95	Prognostic implication of right ventricular involvement in peripartum cardiomyopathy: a cardiovascular magnetic resonance study. <i>ESC Heart Failure</i> , 2015, 2, 139-149.	3.1	62
96	Rationale and design of a randomized, controlled multicentre clinical trial to evaluate the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy. <i>Clinical Research in Cardiology</i> , 2015, 104, 911-917.	3.3	55
97	Peripartum cardiomyopathy: current management and future perspectives. <i>European Heart Journal</i> , 2015, 36, 1090-1097.	2.2	196
98	Emerging translational approaches to target STAT3 signalling and its impact on vascular disease. <i>Cardiovascular Research</i> , 2015, 106, 365-374.	3.8	80
99	Pharmacological targeting of actin-dependent dynamin oligomerization ameliorates chronic kidney disease in diverse animal models. <i>Nature Medicine</i> , 2015, 21, 601-609.	30.7	100
100	Evidence of autoantibodies against cardiac troponin I and sarcomeric myosin in peripartum cardiomyopathy. <i>Basic Research in Cardiology</i> , 2015, 110, 60.	5.9	51
101	Schwangerschaftsassozierte Kardiomyopathie. , 2015, , 1-13.		0
102	Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function: value of the wearable cardioverter/defibrillator. <i>European Journal of Heart Failure</i> , 2014, 16, 1331-1336.	7.1	121
103	Opposing roles of Akt and STAT3 in the protection of the maternal heart from peripartum stress. <i>Cardiovascular Research</i> , 2014, 101, 587-596.	3.8	73
104	Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. <i>European Heart Journal</i> , 2014, 35, 932-941.	2.2	167
105	EURObservational Research Programme: a worldwide registry on peripartum cardiomyopathy (PPCM) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on PPCM. <i>European Journal of Heart Failure</i> , 2014, 16, 583-591.	7.1	99
106	Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. <i>European Heart Journal</i> , 2014, 35, 2165-2173.	2.2	159
107	Targeting myocardial remodelling to develop novel therapies for heart failure. <i>European Journal of Heart Failure</i> , 2014, 16, 494-508.	7.1	90
108	Pathophysiology and epidemiology of peripartum cardiomyopathy. <i>Nature Reviews Cardiology</i> , 2014, 11, 364-370.	13.7	194

#	ARTICLE	IF	CITATIONS
109	oxLDL induces inflammatory responses in vascular smooth muscle cells via urokinase receptor association with CD36 and TLR4. <i>Journal of Molecular and Cellular Cardiology</i> , 2014, 66, 72-82.	1.9	89
110	Improvement of biological age by physical activity. <i>International Journal of Cardiology</i> , 2014, 176, 1187-1189.	1.7	32
111	Focus on pregnancy-mediated heart and vascular disease. <i>Cardiovascular Research</i> , 2014, 101, 543-544.	3.8	4
112	Expression of fibulin-6 in failing hearts and its role for cardiac fibroblast migration. <i>Cardiovascular Research</i> , 2014, 103, 509-520.	3.8	25
113	Small molecule-mediated refolding and activation of myosin motor function. <i>ELife</i> , 2014, 3, e01603.	6.0	47
114	STAT3, a key regulator of cell-to-cell communication in the heart. <i>Cardiovascular Research</i> , 2014, 102, 281-289.	3.8	84
115	Cardiovascular Disorders in Pregnancy: Diagnosis and Management. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2013, 27, 821-834.	2.8	14
116	Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. <i>Basic Research in Cardiology</i> , 2013, 108, 366.	5.9	266
117	Article Commentary: Acute Heart Failure: Is it Peripartum Cardiomyopathy or Not?. <i>Obstetric Medicine</i> , 2013, 6, 42-44.	1.1	1
118	Peripartum cardiomyopathy. <i>Current Opinion in Critical Care</i> , 2013, 19, 397-403.	3.2	10
119	Predictors of outcome in 176 South African patients with peripartum cardiomyopathy. <i>Heart</i> , 2013, 99, 308-313.	2.9	121
120	The STAT3 Pathway and Downstream Mechanisms in Cardiac Remodeling: Friend or Foe. , 2013, , 347-364.		1
121	MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. <i>Journal of Clinical Investigation</i> , 2013, 123, 2143-2154.	8.2	400
122	Mirâ¼17-92 Identifies BCL2 As a Therapeutic Target In BCR-ABL Positive B-Lineage Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 835-835.	1.4	0
123	Protective Function of STAT3 in CVB3-Induced Myocarditis. <i>Cardiology Research and Practice</i> , 2012, 2012, 1-11.	1.1	20
124	STAT3 regulation of and by microRNAs in development and disease. <i>Jak-stat</i> , 2012, 1, 143-150.	2.2	32
125	Circulating microparticles as indicators of peripartum cardiomyopathy. <i>European Heart Journal</i> , 2012, 33, 1469-1479.	2.2	56
126	Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. <i>Nature</i> , 2012, 485, 333-338.	27.8	450

#	ARTICLE	IF	CITATIONS
127	16-kDa Prolactin and Bromocriptine in Postpartum Cardiomyopathy. <i>Current Heart Failure Reports</i> , 2012, 9, 174-182.	3.3	42
128	Nebivolol Exerts Beneficial Effects on Endothelial Function, Early Endothelial Progenitor Cells, Myocardial Neovascularization, and Left Ventricular Dysfunction Early After Myocardial Infarction Beyond Conventional β -Blockade. <i>Journal of the American College of Cardiology</i> , 2011, 57, 601-611.	2.8	111
129	Long-term outcome of Peripartum cardiomyopathy in a population with high seropositivity for Human Immunodeficiency Virus. <i>International Journal of Cardiology</i> , 2011, 147, 202-208.	1.7	75
130	Erythropoietin Preserves the Endothelial Differentiation Capacity of Cardiac Progenitor Cells and Reduces Heart Failure during Anticancer Therapies. <i>Cell Stem Cell</i> , 2011, 9, 131-143.	11.1	68
131	ESC Guidelines on the management of cardiovascular diseases during pregnancy: The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2011, 32, 3147-3197.	2.2	1,694
132	STAT3 and cardiac remodeling. <i>Heart Failure Reviews</i> , 2011, 16, 35-47.	3.9	84
133	Left bundle branch block during pregnancy as a sign of imminent peripartum cardiomyopathy. <i>European Heart Journal</i> , 2011, 32, 1076-1076.	2.2	8
134	Signal transducer and activator of transcription 3-mediated regulation of miR-199a-5p links cardiomyocyte and endothelial cell function in the heart: a key role for ubiquitin-conjugating enzymes. <i>European Heart Journal</i> , 2011, 32, 1287-1297.	2.2	119
135	Low-dose Erythropoietin reduces risk of heart failure induced by anti-cancer therapy. <i>Oncotarget</i> , 2011, 2, 825-825.	1.8	1
136	Prolactin: a new therapeutic target in peripartum cardiomyopathy. <i>Heart</i> , 2010, 96, 1352-1357.	2.9	47
137	Continuous Glycoprotein-130-mediated Signal Transducer and Activator of Transcription-3 Activation Promotes Inflammation, Left Ventricular Rupture, and Adverse Outcome in Subacute Myocardial Infarction. <i>Circulation</i> , 2010, 122, 145-155.	1.6	140
138	Bromocriptine treatment associated with recovery from peripartum cardiomyopathy in siblings: two case reports. <i>Journal of Medical Case Reports</i> , 2010, 4, 80.	0.8	31
139	Evaluation of Bromocriptine in the Treatment of Acute Severe Peripartum Cardiomyopathy. <i>Circulation</i> , 2010, 121, 1465-1473.	1.6	429
140	Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , 2010, 12, 767-778.	7.1	787
141	Peripartum Cardiomyopathy: Role of STAT-3 and Reactive Oxygen Species. , 2010, , 317-337.		0
142	Reviewing peripartum cardiomyopathy: current state of knowledge. <i>Future Cardiology</i> , 2009, 5, 175-189.	1.2	47
143	Management of peripartum cardiomyopathy. <i>Current Heart Failure Reports</i> , 2008, 5, 238-244.	3.3	12
144	Peripartum cardiomyopathy—a new treatment option by inhibition of prolactin secretion. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 199, e5-e6.	1.3	58

#	ARTICLE	IF	CITATIONS
145	The myocardial JAK/STAT pathway: From protection to failure. , 2008, 120, 172-185.		304
146	Peripartum Cardiomyopathy: Recent Insights in its Pathophysiology. Trends in Cardiovascular Medicine, 2008, 18, 173-179.	4.9	90
147	Cardioprotection by Ischemic Postconditioning Is Lost in Aged and STAT3-Deficient Mice. Circulation Research, 2008, 102, 131-135.	4.5	257
148	Reversal of IFN α 3, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. European Journal of Heart Failure, 2008, 10, 861-868.	7.1	162
149	Disease-Modifying Mutations in Familial Hypertrophic Cardiomyopathy. Circulation, 2008, 117, 1775-1777.	1.6	10
150	Postpartum Cardiomyopathy. Deutsches Ärztblatt International, 2008, 105, 751-6.	0.9	17
151	MYOCARDIAL AUTOANTIBODIES AND THEIR CLINICAL SIGNIFICANCE. , 2007, , 355-365.		1
152	A Cathepsin D-Cleaved 16 kDa Form of Prolactin Mediates Postpartum Cardiomyopathy. Cell, 2007, 128, 589-600.	28.9	736
153	Recovery From Postpartum Cardiomyopathy in 2 Patients by Blocking Prolactin Release With Bromocriptine. Journal of the American College of Cardiology, 2007, 50, 2354-2355.	2.8	103
154	Survival pathways in hypertrophy and heart failure: The gp130-STAT3 axis. Basic Research in Cardiology, 2007, 102, 393-411.	5.9	172
155	Molecular Mechanisms in Heart Failure. Journal of the American College of Cardiology, 2006, 48, A56-A66.	2.8	118
156	Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. European Heart Journal, 2006, 27, 441-446.	2.2	273
157	JunD attenuates phenylephrine-mediated cardiomyocyte hypertrophy by negatively regulating AP-1 transcriptional activity. Cardiovascular Research, 2006, 71, 108-117.	3.8	35
158	Preclinical Testing of Tissue-Engineered Heart Valves Re-Endothelialized Under Simulated Physiological Conditions. Circulation, 2006, 114, 1559-65.	1.6	115
159	STAT3-Mediated Activation of Myocardial Capillary Growth. Trends in Cardiovascular Medicine, 2005, 15, 152-157.	4.9	58
160	Many good reasons to have STAT3 in the heart. , 2005, 107, 131-137.		99
161	Lack of JunD Promotes Pressure Overload-Induced Apoptosis, Hypertrophic Growth, and Angiogenesis in the Heart. Circulation, 2005, 112, 1470-1477.	1.6	60
162	Increased Collagen Deposition and Diastolic Dysfunction but Preserved Myocardial Hypertrophy After Pressure Overload in Mice Lacking PKC μ . Circulation Research, 2005, 96, 748-755.	4.5	81

#	ARTICLE	IF	CITATIONS
163	Signal Transducer and Activator of Transcription 3 Is Required for Myocardial Capillary Growth, Control of Interstitial Matrix Deposition, and Heart Protection From Ischemic Injury. <i>Circulation Research</i> , 2004, 95, 187-195.	4.5	345
164	Regulation of Proangiogenic Factor CCN1 in Cardiac Muscle. <i>Circulation</i> , 2004, 109, 2227-2233.	1.6	104
165	Allopurinol Attenuates Left Ventricular Remodeling and Dysfunction After Experimental Myocardial Infarction. <i>Circulation</i> , 2004, 110, 2175-2179.	1.6	188
166	Alterations in Janus Kinase (JAK)-Signal Transducers and Activators of Transcription (STAT) Signaling in Patients With End-Stage Dilated Cardiomyopathy. <i>Circulation</i> , 2003, 107, 798-802.	1.6	135
167	Role of interleukin-6 for left ventricular remodeling and survival after experimental myocardial infarction. <i>FASEB Journal</i> , 2003, 17, 1-20.	0.5	113
168	Expression of CYR61, an Angiogenic Immediate Early Gene, in Arteriosclerosis and Its Regulation by Angiotensin II. <i>Circulation</i> , 2002, 106, 254-260.	1.6	103
169	TNF- α decreases β -MHC expression by a NO mediated pathway: role of E-box transcription factors for cardiomyocyte specific gene regulation. <i>Cardiovascular Research</i> , 2002, 53, 460-469.	3.8	11
170	Role of NAD(P)H Oxidase in Angiotensin II-Induced JAK/STAT Signaling and Cytokine Induction. <i>Circulation Research</i> , 2000, 87, 1195-1201.	4.5	256
171	Expression of Angiotensin II and Interleukin 6 in Human Coronary Atherosclerotic Plaques. <i>Circulation</i> , 2000, 101, 1372-1378.	1.6	608